Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
MBRX
#4446
Moleculin Biotech, Inc.
2.040
0
USD
0.00%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
0.00%
Monthly Change
-35.24%
6 month change
-35.24%
Year Change
-35.24%
Previous Close
2.040
0
Open
2.020
0
Bid
2.040
0
Ask
2.043
0
Low
2.005
0
High
2.110
0
Volume
83
Markets
US Stock Market
Healthcare
MBRX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
120.08 K
560.02 K
565.1 K
1.21 M
2.04 M
—
Valuation ratios
Enterprise value
-9.06 M
-3.33 M
-7.17 M
-7.19 M
-5.62 M
-23.31 M
Price to earnings ratio
-0
-0.01
0.01
0.01
-0.01
-0.01
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-0
-0.01
-0.01
-0
-0.01
-0.03
Price to book ratio
0
0.04
0
0
0.04
0.08
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.32
0.14
0.31
0.38
1.25
2.07
Return on equity %
0.99
0.38
153.24
1.14
0.94
155.71
Return on invested capital %
241.54
226
203.14
189.17
189.11
807.42
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
2.08
0.97
1.35
1.15
1.39
4.86
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
41.15
36.91
12.21
8.99
4.84
62.95
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
63.3
31.06
20.64
12.17
4.49
68.37
Net current asset value per share
78.12
37.71
24.99
14.61
5.28
82.6
Tangible book value per share
-24.7
-37.53
-29.71
-6.41
10.57
-63.09
Working capital per share
40.47
-1.2
6.54
1.87
1.48
8.69
Book value per share
50.34
43.41
0.11
11.54
18.04
73.1
News
Moleculin Biotech releases CEO update on leukemia trial
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.54%
Moleculin Biotech stock plunges after warrant exercise agreement
Moleculin Biotech raises $8.3 million through warrant exercise
Moleculin Biotech stock rises as AML drug trial shows promising results
Moleculin reports promising early data in pivotal AML treatment trial
Moleculin Biotech stock rises after securing key Japanese patent
Moleculin receives patent allowance in Japan for Annamycin preparation method
Moleculin launches CEO Corner to enhance investor communication
Moleculin Biotech stockholders approve warrant issuance, reject name change
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials
Moleculin expects first MIRACLE trial data readout in Q1 2026